Hematology

Thoracic Malignancies

Questions discussed in this category

How do you manage anticoagulation for patients with DVT/PE who have brain metastases?

Some medical oncologists tend to hold anticoagulation in patients who develop brain metastases for fear of causing intracranial hemorrhage. Is there a...

4 Answers available

Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?

1 Answer available

How do you counsel patients on the risk of thromboembolic complications with use of immunotherapy in NSCLC?

Given recent data in Blood (Moik et al, 2021), and the potentially overlapping risks with other clinical factors associated with NSCLC. Will you alte...

3 Answers available

What volume and dose would you use for a Stage I MALT lymphoma of the lung?

Would you use a similar dose and fractionation as gastric MALT (30Gy in 1.5 Gy fractions)?

2 Answers available

Papers discussed in this category

Blood, 2015-07-23

Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Apr 19

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update.

Cancer, 2024 Jan 30

Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients.

Haematologica, 2025 Feb 06

Multinational cohort study of intracranial hemorrhage in patients with brain metastases receiving anticoagulation.

Hematology. American Society of Hematology. Education Program, 2024 Dec 06

Management of anticoagulation in patients with brain metastasis.

Radiother Oncol, 2011 Jun 12

Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.

Int. J. Radiat. Oncol. Biol. Phys., 2012 Mar 13

Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients.

The New England journal of medicine, 2016-11-10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018-05-31

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018-06-14

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Lancet (London, England), 2019-05-04

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Lung cancer (Amsterdam, Netherlands), 2012-12

Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer.

N Engl J Med,

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Blood,

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.

Cancers (Basel), 2019 Dec 25

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

Related Topics in Hematology